These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 7055818)
1. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice. Sirotnak FM; DeGraw JI; Chello PL; Moccio DM; Dorick DM Cancer Treat Rep; 1982 Feb; 66(2):351-8. PubMed ID: 7055818 [No Abstract] [Full Text] [Related]
2. Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice. Sirotnak FM; DeGraw JI; Moccio DM; Dorick DM Cancer Treat Rep; 1978 Jul; 62(7):1047-52. PubMed ID: 688246 [TBL] [Abstract][Full Text] [Related]
3. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. Sirotnak FM; Schmid FA; Samuels LL; DeGraw JI NCI Monogr; 1987; (5):127-31. PubMed ID: 2448650 [TBL] [Abstract][Full Text] [Related]
4. Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors. Sirotnak FM; Donsback RC Cancer Res; 1975 Jul; 35(7):1737-44. PubMed ID: 1169115 [TBL] [Abstract][Full Text] [Related]
5. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Sirotnak FM; DeGraw JI; Moccio DM; Samuels LL; Goutas LJ Cancer Chemother Pharmacol; 1984; 12(1):18-25. PubMed ID: 6690069 [TBL] [Abstract][Full Text] [Related]
6. Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell. Sirotnak FM; Donsbach RC Cancer Res; 1972 Oct; 32(10):2120-6. PubMed ID: 4404161 [No Abstract] [Full Text] [Related]
7. Similar characteristics of folate analogue transport in vitro in contrast to varying dihydrofolate reductase levels in epithelial cells at different stages of maturation in mouse small intestine. Sirotnak FM; Moccio DM; Yang CH Cancer Res; 1984 Nov; 44(11):5204-11. PubMed ID: 6488181 [TBL] [Abstract][Full Text] [Related]
8. The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist. Skeel RT; Sawicki WL; Cashmore AR; Bertino JR Cancer Res; 1973 Nov; 33(11):2972-6. PubMed ID: 4748449 [No Abstract] [Full Text] [Related]
9. Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Kuehl M; Brixner DI; Broom AD; Avery TL; Blakley RL Cancer Res; 1988 Mar; 48(6):1481-8. PubMed ID: 2449950 [TBL] [Abstract][Full Text] [Related]
10. Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action. Rumberger BG; Barrueco JR; Sirotnak FM Cancer Res; 1990 Aug; 50(15):4639-43. PubMed ID: 2369741 [TBL] [Abstract][Full Text] [Related]
11. Reduced forms of aminopterin and methotrexate in L1210 lymphoma. Makulu DR; Fölsch E J Natl Cancer Inst; 1977 Jul; 59(1):245-9. PubMed ID: 875056 [TBL] [Abstract][Full Text] [Related]
12. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Schmid FA; Sirotnak FM; Otter GM; DeGraw JI Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells. Chello PL; Sirotnak FM; Dorick DM; Donsbach RC Cancer Res; 1977 Dec; 37(12):4297-303. PubMed ID: 922722 [No Abstract] [Full Text] [Related]
15. Stereochemical characteristics of the folate-antifolate transport mechanism in L1210 Leukemia cells. Sirotnak FM; Donsbach RC Cancer Res; 1974 Feb; 34(2):371-7. PubMed ID: 4855750 [No Abstract] [Full Text] [Related]
16. Reactivation of dihydrofolate reductase inhibted by methotrexate or aminopterin. Jackson RC; Niethammer D; Hart LI Arch Biochem Biophys; 1977 Aug; 182(2):646-56. PubMed ID: 561567 [No Abstract] [Full Text] [Related]
17. Competitive dihydrofolate reductase binding assay of triazinate (NSC-139105), methasquin (NSC-122870), and aminopterin (NSC739). Myers CE; Eliot HM; Chabner BA Cancer Treat Rep; 1976 May; 60(5):615-6. PubMed ID: 1033031 [No Abstract] [Full Text] [Related]
18. Analog specific aberrancies in antifolate inhibition of L1210 cell dihydrofolate reductase. Sirotnak FM; Chello PL; Moccio DM; Piper JR; Montgomery JA; Parham JC Biochem Pharmacol; 1980 Dec; 29(24):3293-8. PubMed ID: 7213404 [No Abstract] [Full Text] [Related]
19. Structural design, biochemical properties, and evidence for improved therapeutic activity of 5-alkyl derivatives of 5-deazaaminopterin and 5-deazamethotrexate compared to methotrexate in murine tumor models. Sirotnak FM; Schmid FA; Otter GM; Piper JR; Montgomery JA Cancer Res; 1988 Oct; 48(20):5686-91. PubMed ID: 3167828 [TBL] [Abstract][Full Text] [Related]
20. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models. Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]